PMID- 26674737
OWN - NLM
STAT- MEDLINE
DCOM- 20170726
LR  - 20170817
IS  - 1969-6213 (Electronic)
IS  - 1774-024X (Linking)
VI  - 12
IP  - 9
DP  - 2016 Oct 20
TI  - Assessing the cardiology community position on transradial intervention and the 
      use of bivalirudin in patients with acute coronary syndrome undergoing invasive 
      management: results of an EAPCI survey.
PG  - 1154-1163
LID - EIJ-D-15-00044 [pii]
LID - 10.4244/EIJY15M12_01 [doi]
AB  - AIMS: Our aim was to report on a survey initiated by the European Association of 
      Percutaneous Cardiovascular Interventions (EAPCI) collecting the opinion of the 
      cardiology community on the invasive management of acute coronary syndrome (ACS), 
      before and after the MATRIX trial presentation at the American College of 
      Cardiology (ACC) 2015 Scientific Sessions. METHODS AND RESULTS: A web-based 
      survey was distributed to all individuals registered on the EuroIntervention 
      mailing list (n=15,200). A total of 572 and 763 physicians responded to the pre- 
      and post-ACC survey, respectively. The radial approach emerged as the preferable 
      access site for ACS patients undergoing invasive management with roughly every 
      other responder interpreting the evidence for mortality benefit as definitive and 
      calling for a guidelines upgrade to class I. The most frequently preferred 
      anticoagulant in ACS patients remains unfractionated heparin (UFH), due to higher 
      costs and greater perceived thrombotic risks associated with bivalirudin. 
      However, more than a quarter of participants declared the use of bivalirudin 
      would increase after MATRIX. CONCLUSIONS: The MATRIX trial reinforced the 
      evidence for a causal association between bleeding and mortality and triggered 
      consensus on the superiority of the radial versus femoral approach. The belief 
      that bivalirudin mitigates bleeding risk is common, but UFH still remains the 
      preferred anticoagulant based on lower costs and thrombotic risks.
FAU - Adamo, Marianna
AU  - Adamo M
AD  - Thoraxcenter, Erasmus Medical Center, Rotterdam, The Netherlands.
FAU - Byrne, Robert A
AU  - Byrne RA
FAU - Baumbach, Andreas
AU  - Baumbach A
FAU - Haude, Michael
AU  - Haude M
FAU - Windecker, Stephan
AU  - Windecker S
FAU - Valgimigli, Marco
AU  - Valgimigli M
LA  - eng
PT  - Journal Article
PL  - France
TA  - EuroIntervention
JT  - EuroIntervention : journal of EuroPCR in collaboration with the Working Group on 
      Interventional Cardiology of the European Society of Cardiology
JID - 101251040
RN  - 0 (Antithrombins)
RN  - 0 (Hirudins)
RN  - 0 (Peptide Fragments)
RN  - 0 (Recombinant Proteins)
RN  - TN9BEX005G (bivalirudin)
SB  - IM
MH  - Acute Coronary Syndrome/*therapy
MH  - Adult
MH  - Antithrombins/*therapeutic use
MH  - *Attitude of Health Personnel
MH  - Cardiology
MH  - Femoral Artery
MH  - Hirudins
MH  - Humans
MH  - Middle Aged
MH  - Peptide Fragments/*therapeutic use
MH  - Percutaneous Coronary Intervention/*methods
MH  - *Radial Artery
MH  - Recombinant Proteins/therapeutic use
MH  - Societies, Medical
MH  - Surveys and Questionnaires
EDAT- 2016/10/19 06:00
MHDA- 2017/07/27 06:00
CRDT- 2015/12/18 06:00
PHST- 2016/10/19 06:00 [pubmed]
PHST- 2017/07/27 06:00 [medline]
PHST- 2015/12/18 06:00 [entrez]
AID - EIJ-D-15-00044 [pii]
AID - 10.4244/EIJY15M12_01 [doi]
PST - ppublish
SO  - EuroIntervention. 2016 Oct 20;12(9):1154-1163. doi: 10.4244/EIJY15M12_01.